Syngene International · forward-looking guidance across the available source record.
Guidance tracker
Management maintained full-year guidance despite expecting a shift in revenue mix toward development and manufacturing services. Constant currency growth of 19% in Q1 tracks in line with this target.
Expected to remain around 30% if revenues are recognized at average hedge rate of ~INR 81/USD. Higher realized hedge rates could equate to lower margins due to hedge losses in P&L.
Due to Stelis acquisition replacing internal biologics expansion CapEx, overall CapEx guidance for the year lowered. Initial guidance was $100 million with net capital guidance of $15 million.
The 20,000L biologics facility expected to reach positive contribution to bottom line from FY2027, with 1x asset turnover achievable within five years. EBITDA margin expected to be in line with company average from FY2039.
FY25 EBITDA margin expected to be similar to FY24 (high 20s%), with sequential margin improvement as revenue builds through H2. Q1 margin of 22% is the trough.
Revenue expected to be largely flat in H1 with momentum building in H2, driven by biotech funding rebound and China diversification wins converting from pilots to contracts.
Full-year PAT growth expected to be in single digits, consistent with prior guidance, as operating leverage kicks in with revenue recovery.
Biologics manufacturing facility acquired from Stelis is on track to start operations in H2 FY25, with business development activity commencing post-validation.
Management reaffirmed guidance for mid-single-digit reported revenue growth, adjusting for client inventory rebalancing in commercial biologics manufacturing. Underlying business expected to grow in early teens.
Full year EBITDA margins expected in mid-20s, with some degrowth impact due to increased depreciation as Unit 3 and Bayview facilities come online. Q1 margins at 24% support this trajectory.
US-based Bayview facility revalidation and integration efforts on track; expect to operationalize in second half of FY26. Facility offers versatility with three discrete suites and has generated healthy interest from potential customers.
Normalized effective tax rate expected around 24% for FY26. Q1 reported ETR of 14% included favorable one-time tax adjustment on gratuity fund transfer; normalized ETR was 21%.
Full-year revenue guidance adjusted from high-teens to mid-teens constant currency growth due to near-term slowdown in U.S. biotech demand. Reported growth will be higher due to currency tailwinds. Strong Q4 recovery expected.
Full-year EBITDA margin guidance maintained at approximately 30%. H1 margin was 28%, implying H2 margins will be higher than H1 to achieve full-year target.
CapEx guidance revised down from $85M to $80M; $30M executed in H1, another $20M already committed. Over 50% allocated to research business, ~$5-7M for Stelis facility upgrades, remainder to small molecule CDMO and enterprise initiatives.
Acquisition of multimodal biopharma facility from Stelis Biopharma is progressing through closing conditions. Expected to close in the current quarter. Pre-operational expenses will be capitalized post-acquisition.
Revenue growth guidance maintained, but management expects outcomes at the lower half of the guided range based on current visibility, with momentum building in H2.
H1 margin was 25% vs 27% last year; margin recovery expected in H2 driven by sequential revenue growth and operating leverage.
Q2 CapEx was $12 million; bulk of spending directed toward biologics facility upgrade (Unit 3) and research services expansion in Hyderabad.
The Stelis acquisition facility is on track for commissioning in the second half, converting from vaccine production capability to antibody manufacturing.
Management maintained guidance for mid-single-digit revenue growth on both reported and constant currency basis, driven by research services momentum and recovery in biologics H2.
Full-year EBITDA margins expected in mid-20s (vs 22% in Q2) as H2 typically stronger than H1; transient year due to new facility ramp-up costs.
PAT expected to decline year-on-year due to higher depreciation from Bangalore Unit 3 and Bayview facility preparations alongside lower margins.
U.S. biologics manufacturing facility in Baltimore remains on track to commence operations in second half of FY2026, with monetization beginning after trial batches.
Given slower Q3 growth in Discovery services, management now expects full-year revenue growth to land in double-digits rather than the previously guided mid-teens range.
Q4 is anticipated to deliver better revenue than Q3 on a sequential basis, potentially marking one of the largest revenue quarters of FY24.
Full-year CapEx guidance lowered to approximately $60 million from prior guidance of $80 million, moderated to balance research business investments with revenue growth visibility.
The recently acquired Stelis Biopharma facility requires revalidation and upgrading through calendar 2024, with commercial production expected to begin in the second half of next financial year.
After 9M revenue up 2% YoY and Q3 returning to 11% growth, management expects single-digit revenue growth for FY25, down from earlier high single-digit to low double-digit guidance.
Despite Q3's strong 23% EBITDA growth and margin expansion, 9M EBITDA is flat YoY. Full-year EBITDA guidance remains flat, reflecting first-half weakness.
Operating EBITDA margins expected around last year's levels in the high 20s range, with Q4 margins continuing the recovery trajectory seen in Q3.
CapEx program remains on track at approximately $60 million by year-end, with roughly 50% allocated to research services and 25% to biologics (Unit 3 upgrade).
The company revised its full-year guidance downward from mid-single-digit growth to a 3%-5% revenue decline, driven by the ongoing impact from the single large molecule product from its largest biologics customer. The guidance is in constant currency terms.
Full-year operating EBITDA margin is expected in the range of 22%-23%, a significant compression from 27% in FY25, reflecting lower revenue, higher operating costs from new facilities, and the hedge loss impact.
The company continues to invest in building capabilities and technologies across research services and CDMO, including DMPK Biology, ADC Labs, oral solid dosage capabilities, and Stelis facility integration.
The normalized effective tax rate for the quarter was 22.8% compared to 22.2% in the same quarter last year, with full-year ETR expected in the 21%-23% range.
Management expects improved demand situation with high single-digit to low double-digit growth on constant currency basis, building from 6% constant currency growth in FY24. First half expected to be relatively flat to low single-digit, with stronger second half driven by biotech funding recovery and pharma diversification trends.
Operating EBITDA margin expected to be roughly stable year-over-year, reflecting continued investments in capacity and capabilities while benefiting from operational efficiencies.
Profit after tax growth anticipated to be single-digit due to headwind from increased effective tax rate rising to approximately 23% from underlying 21.5% in FY24, partially offset by operational improvements.
Planned capital expenditure of $60 million with approximately 50% for research services (Hyderabad land development, automation, Bangalore facility), 40% for CDMO business including Stelis biologics plant qualification, and 15% for digitization and ESG initiatives.
Expected broad-based growth across research services, small and large molecule CDMO businesses, underpinned by pipeline visibility and pilot program conversions.
Adjusted for client inventory rebalancing in biologics commercial manufacturing (Zoetis animal health product normalizing to ~$50M annual run rate from elevated pre-launch/launch volumes).
Margins expected to moderate from 28.6% in FY25 due to operating costs from new Unit 3 and Baltimore facilities coming online, with gestation and ramp-up period.
PAT expected to decline due to increased depreciation from new facilities and higher effective tax rate rising to 26% as SEZ units exit tax holidays.
FY2027 will be a transition year with flat revenue performance as Librela impact winds down in Q1-Q2, with growth weighted toward H2 FY27 as new contracts ramp up. Management expects Q1 FY27 to have pronounced Librela destocking impact.
EBITDA margins expected to be maintained in the mid-twenties through disciplined cost management and sharper operational execution, despite new facility costs being fully baked in.
H2 FY27 expected to be meaningfully stronger than H1 as new contracts ramp up and business momentum improves, with the company expecting to end FY27 on a growth trajectory.
FY2028 onwards expected to deliver stronger growth as the healthy pipeline of deal flows translates into revenue, supported by investments in CDMO, biologics, and emerging AI-enabled service lines.